Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 13th Preview)
-
Regulatory approvals and label changes
FDA approval has been granted for an adjuvant pembrolizumab–belzutifan combination in high-risk, post-surgery clear cell kidney cancer, according to a Dana-Farber-backed report. The regimen pairs an immune checkpoint inhibitor with a hypoxia-inducible factor-2α (HIF-2α) blocker to target residual disease after nephrectomy. The approval expands the adjuvant toolset for clear cell renal cell carcinoma and underscores continued regulator focus on combination strategies in the perioperative setting, where endpoints often hinge on preventing recurrence rather than shrinking existing tumors.
-
Clinical trial results reshape the competitive landscape
Takeda’s zasocitinib scored statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a top-line Phase 3 readout for moderate-to-severe plaque psoriasis, reported from the Latitude Atlas program. Takeda said the superiority held on primary and secondary goals, positioning its oral TYK2 inhibitor to challenge the current standard-of-care landscape. The result adds urgency for payers and clinicians weighing injectable vs oral options in psoriasis as multiple oral and pipeline TYK2 assets vie for market share.
-
Financing and IPO momentum in biotech
Parabilis completed a $770.5 million IPO after underwriters exercised their full overallotment option, according to the company’s public-equity reporting. The conformationally stabilized peptide developer said it closed at the top end of the deal range and has now raised more than $1 billion across recent offerings when including earlier capital. The listing continues a run of unusually large biopharma IPOs in 2026, reinforcing investor appetite for late-stage-ready platforms and modality diversification, particularly in areas like hard-to-modulate targets.
-
Oncology pipeline and next-generation immunotherapy
Oricell advanced its GPC3-directed strategy in liver cancer, moving its autologous CAR T therapy Ori-C101 into a confirmatory registration Phase 2 trial in patients with GPC3-positive advanced hepatocellular carcinoma. The company positions the program as the first GPC3 immune cell therapy reaching that stage and, as described, the first CAR T dedicated to liver cancer to enter this phase. If confirmatory data translate to durable responses in the target population, Ori-C101 could reshape how CAR T is prioritized for solid tumors where hepatic delivery and persistence remain key hurdles.
-
New platform funding for gene medicines
SonoThera raised an oversubscribed $125 million in Series B financing, using the capital to advance ultrasound-mediated delivery genetic medicines into clinical development. The round was led by Vida Ventures with participation from ARK Invest, Bayer’s venture unit Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures, Otsuka, and multiple strategic and financial backers. The company plans to move its lead Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease programs through clinical timelines and to scale its RIPPLE delivery and PORE payload engineering platforms. SonoThera expects a first DMD clinical trial in 2027.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.